to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Edgar Miles Bronfman, Jr. (born May 16, 1955), formerly CEO of Seagram and vice-chairman of Vivendi Universal, has been CEO of Warner Music since 2004. He is the son of Edgar Miles Bronfman and the grandson of Samuel
Bronfman, one of the most wealthy and influential Jewish families in Canada. Edgar Jr. is the second of five children, and was indicated by his grandfather in 1971 as being suitable as the heir to the Seagram Company. From his early days,
Bronfman's interest in the arts was apparent. He was particularly active in school theatre, an interest his parents supported by donating to construct The Ann and Edgar Bronfman Theatre during a 1967 expansion at The Collegiate School, the
prestigious private school in Manhattan which Edgar Jr. attended. Edgar Jr. and his classmates created a documentary film of the school that spawned the Collegiate Film Festival, an event that gained positive press in The Los Angeles Times
and The Village Voice. Bronfman proceeded to a brief career in entertainment in the 1970s as a film and Broadway producer. The summer before his final year of high school, in 1972, he was a credited producer on the film, The Blockhouse.
Despite his inexperience, Bronfman's involvement was accepted because of his connections and access to financing. In return, he learned many of the tricks of the trade by watching his more experienced peers. In 1973, Bronfman began a
songwriting career under the pseudonyms Junior Miles and Sam Roman. He often collaborated with Bruce Roberts on songs like "Whisper in the Dark", which he gave to Dionne Warwick to record in thanks for introducing him to his first wife,
Sherry. His Efer Productions company was signed by Universal Studios in 1977 to a three-year movie production contract. He produced the unsuccessful film The Border, which starred Jack Nicholson. In 1982, Bronfman returned to the Seagram
Company, spending three months learnin
What can extreme surfing and World of Warcraft teach the enterprise? Independent Co-Chairman of the Deloitte Center for the Edge and former Xerox PARC Chief Scientist John Seely Brown holds them as examples of the power of frequent benchmarking and full industry info-share. He also uses them to show how the core ecosystem can be made stronger by sharing knowledge gathered from learning on the edge. In addition, Seely Brown touches upon his theory of a monumental economic shift from a push to a pull economy as outlaid in his 2010 book, The Power of Pull: How Small Moves, Smartly Made, Can Set Big Things in Motion.
Would you rather buy the new Apple product or save that money in an interest bearing account? When is the right time for a person to start saving? I was lucky enough to have great parents that instilled the importance of saving in my brain. But I also had a different "saving gene" than my three older sisters who tended to and still do spend more than me.
Adam Coomes is a prime example of an entrepreneur who has seen the best of times and the worst of times. He has been a part of several startups and has gone through the peaks and valleys of these experiences. They've consisted of fast-paced ventures and ventures that have been put on the backburner. He has never worked in the corporate world and never intends to. Adam will always be an entrepreneur.
Baby boomers are micromanagers, work hard, do not understand technology, are stubborn and want to destroy the planet. Millennials are lazy, entitled, tech savvy, want to save the world and don't know how to communicate in person. Although the generalizations of baby boomers and millennials vary, they do share one similar characteristic, they both share particular entrepreneurial characteristics. Millennials crave freedom and earning potential. Baby boomers have a desire to build something.
I have spent the majority of my adult life investing my own and other people's money in entrepreneurs. That's why I know the U.S. has a serious problem on its hands.
Although the stock market has tentatively rebounded, funding for the one area in which America has a distinct competitive advantage--that is, new company formation--is in scary decline. That may be a familiar refrain by now, but that doesn't make the ramifications any less real. Or less dangerous.
G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid
and sustained developers. He currently serves as Chairman of the Boards of Pharmasset, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (Amex: DMI), Targacept (NASDAQ: TRGT), Proventys and Phytomedics. Prior to
founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr.
Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). Mr. Burrill is a founder of the Foundation for the National Medals of Science and Technology and
currently serves on its Board of Directors. Some of his not for profit activities include serving on the Boards of Directors for the Bay Area Science Infrastructure Consortium, BayBio, the California Healthcare Institute, the
Exploratorium, The Kellogg Center for Biotechnology, Research America, Campaign for Medical Research, The National Health Museum, and the University of California, San Francisco (UCSF) Foundation. He is also the Chairman of the Mayor's
Biotech Advisory Committee (MAYBAC).
Steve Burrill, CEO of Burrill &amp; Co., provides an overview of the life sciences industry, reflecting on insights he has gained throughout his career. Along the way, he shares his laws of survival and anecdotes that relate the keys to his success in the areas of biotechnology, venture capital and merchant banking.
Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than forty new technology based ventures, over half of which have already become public companies. He formed the first
Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 90 Life Sciences
companies which are developing hundreds of products to treat major underserved medical needs representing huge markets in the nearly two trillion dollar healthcare sector. Brook was the founding President and then Chairman of four
biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is currently on the Board of Directors of eight companies, most recently joining
CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, Nanofluidics and XDx, Inc.. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals,
Pharmacopeia, Ligand Pharmaceuticals (Chairman), Hybritech (Chairman), Genprobe, Nanogen, and others. These companies have pioneered the medical uses of molecular biology, monoclonal antibodies, molecular diagnostics and genomics. Brook
was President and a Director of the Western Association of Venture Capitalists and is a contributing author to the book "Guide to Venture Capital". He is currently a Board member of the University of California at San Francisco Medical
Foundation, the California Healthcare Institute, the New Schools Foundation, Stanford's Bio-X Advisory Council, the Stanford Eye Council and TechNet. He is Co-Chair of the current five year, $1.4 billion, UCSF Capital Campaign. He was
formerly a Director of the Entrepreneurs Foundation, t
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.